33rd week of 2011 patent applcation highlights part 43 |
Patent application number | Title | Published |
20110201534 | BENEFIT COMPOSITIONS COMPRISING POLYGLYCEROL ESTERS - The instant disclosure relates to compositions comprising a mixture of polyglycerol partial esters, each having the structure of Formula I | 2011-08-18 |
20110201535 | Expression of Streptomyces Subtilisin Inhibitor (SSI) Proteins In Bacillus and Streptomyces sp. | 2011-08-18 |
20110201536 | METHOD FOR IMPROVING THE CLEANING ACTION OF A DETERGENT OR CLEANING AGENT - The present invention relates to a method for increasing the cleaning performance of a washing or cleaning agent comprising at least one hydrolytic enzyme by addition of a component capable of synergistic interaction with the enzyme. Components capable of such positive synergistic interaction with hydrolytic enzymes include: (i) an amino acid, a polyamino acid, or derivatives thereof; (ii) a biosurfactant; (iii) a microbial metabolite, and a preparation of a microbial culture supernatant that contains at least 2.5 wt % of (i), (ii), or (iii). Additionally, the present invention comprises a method for washing textiles or hard surfaces with an enzymatic washing or cleaning agent that includes at least one of the components (i), (ii), or (iii) capable of increasing the cleaning performance of the washing or cleaning agent through synergistic interaction with the hydrolytic enzyme. | 2011-08-18 |
20110201537 | BENEFIT COMPOSITIONS COMPRISING CROSSLINKED POLYGLYCEROL ESTERS - The instant disclosure relates to fabric and household hard surface treatment compositions comprising a mixture of cross-linked polyglycerol esters molecules each comprising at least two polyglycerol ester moieties having the structure of Formula I | 2011-08-18 |
20110201538 | NEW POLYGLYCEROL ESTERS AND THEIR USE - The present invention relates to polyglycerol partial esters of linear, unsubstituted carboxylic acids with the provisos that the polyglycerol obtained by hydrolysis or alcoholysis of the polyglycerol partial ester comprises an average degree of polymerization of from 2 to 8 and the polydispersity index of said polyglycerol is greater than 0.75. | 2011-08-18 |
20110201539 | DETECTING SUCCINYLACETONE - This invention relates, inter alia, to detecting and/or measuring succinylacetone and one or more additional biological analytes using mass spectrometry. | 2011-08-18 |
20110201540 | Glycosylation of Molecules - Described herein are methods and genetically engineered cells useful for producing an altered N-glycosylation form of a target molecule. Also described are methods and molecules with altered N-glycosylation useful for treating a variety of disorders such as metabolic disorders. | 2011-08-18 |
20110201541 | TISSUE OCCLUDING AGENT - There is provided a bioabsorbable peptide tissue occluding agent that can be applied to large mammals including humans, the peptide tissue occluding agent being obtained by artificial synthesis to avoid concerns of infection by viruses and the like. | 2011-08-18 |
20110201542 | Myeloid Protein Activation of Anti-Inflammatory and Anti-Hypoxic Pathway - Provided are methods to enhance healing of wounds and tissue, especially during or pursuant to psychological and/or physical stress and to protect tissue from deleterious effects associated with oxidative, psychological and/or physical stress, including but not limited to extreme exertion, ischemia, infarct, and damage associated with reperfusion of ischemic or transplanted tissues. | 2011-08-18 |
20110201543 | USE OF TIGHT JUNCTION ANTAGONISTS IN THE TREATMENT OF ACUTE LUNG INJURY AND ACUTE RESPIRATORY DISTRESS - The present application provides compositions and methods for treating acute lung injury and acute respiratory distress syndrome. The methods include administering one or more tight junction antagonists to the lung of a subject in need thereof. | 2011-08-18 |
20110201544 | Compositions and Methods for Inhibiting the Interaction between CFTR and CAL - The present invention features compositions and methods for increasing the cell surface expression of degradation-prone CFTR proteins and preventing or treating cystic fibrosis. The invention provides peptides and peptidomimetics that selectively inhibit the interaction between CAL and mutant CFTR proteins, thereby stabilizing the CFTR and facilitating transport of the same to the cell surface. | 2011-08-18 |
20110201545 | GEL BASED LIVESTOCK FEED, METHOD OF MANUFACTURE AND USE - A method of making a gel-type livestock feed includes initially forming a feed mixture by mixing feed nutrient components, water, alginate, and a calcium component insoluble in water or a sequestrate to inhibit the calcium component from reacting with the alginate. Once the feed mixture is formed, the calcium component is solubilized or the sequestrates affecting the reactivity between the alginate and the calcium component is removed such that a gel feed is formed that includes a gel matrix containing the feed nutrient components. The gel feed may then be fed to the livestock. In another aspect of the present invention, piglets are weaned by feeding the gel feed for at least seven days directly after weaning. The gel feed may also include protein derived from blood with or without egg protein. | 2011-08-18 |
20110201546 | METHODS OF TREATMENT USING SINGLE DOSES OF ORITAVANCIN - Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against a wide range of bacteria. Methods for the treatment, prophylaxis and prevention of bacterial infection and disease in animals, including humans, using a single dose of oritavancin over the course of therapy, are described. | 2011-08-18 |
20110201547 | ENGINEERED POLYPEPTIDE AGENTS FOR TARGETED BROAD SPECTRUM INFLUENZA NEUTRALIZATION - The present invention provides novel agents for broad spectrum influenza neutralization. The present invention provides agents for inhibiting influenza infection by bind to the influenza virus and/or hemagglutinin (HA) polypeptides and/or HA receptors, and reagents and methods relating thereto. The present invention provides a system for analyzing interactions between infolds and the interaction partners that bind to them. | 2011-08-18 |
20110201548 | THERAPEUTIC AGENT FOR ACUTE HEPATITIS OR PROPHYLACTIC/THERAPEUTIC AGENT FOR FULMINANT HEPATITIS - When acute hepatitis progresses to fulminant hepatitis, a large amount of hepatic cells are rapidly broken, and as a result, the prognosis is seriously worsened. Thus, it is important to prognose the progress of acute hepatitis into fulminant hepatitis at an early stage and quickly start an appropriate treatment therefor. Although the prognosis of progress into fulminant hepatitis becomes possible owing to recent advances in test methods and diagnostic techniques, there has been no appropriate prophylactic/therapeutic agent for fulminant hepatitis. The present invention provides a therapeutic agent for acute hepatitis or a prophylactic/therapeutic agent for fulminant hepatitis with little side effect. The problem of the invention was solved by using a composition containing apolipoprotein A-II. | 2011-08-18 |
20110201549 | Enhancement of Bacillus Thuringiensis Cry Toxicities to Lesser Mealworm Alphitobius Diaperinus - The subject invention relates in part to the discovery that BtBooster (BtB) peptides enhance Bt strain and Cry protein toxicity to the lesser mealworm. The subject invention also relates in part to the discovery that Bt | 2011-08-18 |
20110201550 | COMBINATION OF AMIDINE DERIVATIVES WITH CYCLIC DEPSIPEPTIDES - The present invention relates to the combination of aminophenylamidine derivatives with cyclic depsipeptides, to products comprising this combination, and to the use of these active substances in combination for controlling endoparasites in humans and in animals. | 2011-08-18 |
20110201551 | PEPTIDE HAVING ANTI-DIABETIC ACTIVITY AND USE THEREOF - The present invention provides a composition (a blood glucose increase inhibitor) that has an effect of lowering blood glucose level in a hyperglycemic patient and that is therefore used to reduce blood glucose level in the patient. The present invention further provides a composition that is used to prevent or treat diseases caused by hyperglycemia, in particular, diabetes and diabetic complications (a composition for preventing or treating diseases caused by hyperglycemia, an antidiabetic), based on the above-mentioned effect. A feature of the present invention is using a peptide consisting of the amino acid sequence of Leu-Ser-Glu-Leu as an active ingredient. | 2011-08-18 |
20110201552 | ISOLATED NUCLEIC ACID MOLECULE ENCODING A NEUROTROPHIC GROWTH FACTOR - There is disclosed an isolated nucleic acid molecule encoding a human neurotrophic growth factor designated enovin and having the amino acid sequence illustrated in FIG. | 2011-08-18 |
20110201553 | Systemic Pro-hemostatic Effect of Sympathicomimetics with Agonistic Effects on Alfa-Adrenergic and/or Beta-Adrenergic Receptors of the Sympathetic Nervous System, Related to Improved Clot Strength - The present invention relates to a novel use and methods of treatment using sympathicomimetic agonists with pro-hemostatic activity. | 2011-08-18 |
20110201554 | HFSH AQUEOUS FORMULATION - Provided is an aqueous formulation of a human follicle stimulating hormone (hFSH) which is stabilized to maintain the activity of hFSH for a prolonged period of time. The formulation of the present invention is an aqueous formulation comprising a therapeutically effective amount of hFSH stabilized in a phosphate buffer containing glycine, methionine and a non-ionic surfactant, preferably polysorbate 20, which is capable of maintaining the activity of hFSH for an extended period of time. | 2011-08-18 |
20110201555 | NOVEL ESTROGEN RECEPTOR LIGANDS - The invention provides a compound of formula (I) or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt. The invention also provides also provides the use of such compounds in the treatment or prophylaxis of a condition associated with a disease or disorder associated with estrogen receptor activity. | 2011-08-18 |
20110201556 | METHODS OF TREATING CARTILAGE DEFECTS - The present invention provides methods of repairing and regenerating cartilage tissue by administering into the cartilage or the area surrounding the cartilage a composition comprising a therapeutically effective amount of a morphogenic protein. | 2011-08-18 |
20110201557 | METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISORDERS AND ALZHEIMER'S DISEASE AND IMPROVING NORMAL MEMORY - The disclosure relates generally to neurodegenerative disorders and more specifically to a group of presenilin/G-protein/c-src binding polypeptides and methods of use for modulating signaling and progression of Alzheimer's disease. | 2011-08-18 |
20110201558 | Anaplerotic Therapy for Alzheimer's Disease and the Aging Brain - The present invention describes methods and compositions for the treatment of neurodegenerative conditions including Alzheimer's disease (AD) and aging. The present invention discloses an anaplerotic diet therapy for the treatment of AD. The high fat, low carbohydrate diet described in the various embodiments of the present invention increasing circulating ketone bodies, reduces amyloid-β (Aβ) deposition in AD patients, thereby improving cognition and locomotive skills. | 2011-08-18 |
20110201559 | New Optically Pure Compounds for Improved Therapeutic Efficiency - The present invention relates to new optically pure compounds displaying an improved anticancer activity compared to previously known complex mixtures of stereoisomers thereof. Such compounds are of formula (I): wherein each X independently represents any amino acid; n is 0 or 1; m is an integer between 0 and 3; k is an integer of at least 3; Psi is a reduced bond of formula replacing the peptide amide bond between Lys and Pro; and wherein Lys residues in pseudopeptide units of said compound of formula (I) are either all in L configuration or all in D configuration. A method for preparing such compounds, and therapeutic uses thereof are also provided. The synthetic method involves the selective reduction of the peptide bond between Lys and Pro in a dipeptide intermediate with borane. The therapeutic uses are against cancer, inflammation and for wound healing. | 2011-08-18 |
20110201560 | PEPTIDES FOR INHIBITING THE HPV-E6 ONCOPROTEIN - The present invention is concerned with means and methods for diagnosing or treating HPV associated neoplasia or tumors. Specifically, it relates to a peptide comprising an amino acid sequence motif as shown in SEQ ID No: 1. Moreover, contemplated by the present invention are fusion polypeptides, polynucleotides, vectors and host cells based on said peptide. Furthermore, the peptides, fusion polypeptides, polynucleotides, and vectors are suitable as pharmaceutical compositions for treating HPV associated neoplasia or tumors. The peptides and fusion polypeptides are also suitable as diagnostic compositions for diagnosing HPV associated neoplasia or tumors. The present invention also refers to a method of identifying a compound capable of binding to the HPV E6 protein. Finally, a kit is provided for carrying out the aforementioned diagnosis or compound identification. | 2011-08-18 |
20110201561 | TREATMENT OF METASTATIC COLON CANCER WITH B-SUBUNIT OF SHIGA TOXIN - The present invention relates to compositions and methods for treating invasive or metastatic cancer, particularly metastatic colon cancer using the B-submit of shiga toxin. The invention further provides methods of identifying compounds usefully for the treatment of invasive or metastatic cancer, particularly metastatic colon cancer. | 2011-08-18 |
20110201562 | FORMULATIONS AND METHOD FOR TREATING BALDNESS - The present invention includes 1) a novel formulation for the treatment of hair loss comprising oleanolic acid (a 5α-reductase inhibitor), apigenin (a vasodilator), and biotinyl-GHK (a cell metabolism stimulant), 2) a novel additive for the treatment of hair loss comprising oleanolic acid, apigenin, biotinyl-GHK and a delivery agent, 3) a personal care, cosmetic, and/or dermopharmaceutical composition comprising oleanolic acid, apigenin, biotinyl-GHK, and at least one additional ingredient, and 4) a method for treating hair loss comprising the administration of oleanolic acid, apigenin, and biotinyl-GHK. | 2011-08-18 |
20110201563 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS - The present invention relates to chimeric chemical compounds which are used to recruit antibodies to cancer cells, in particular, prostate cancer cells or metastasized prostate cancer cells. The compounds according to the present invention comprise an antibody binding terminus (ABT) moiety covalently bonded to a cell binding terminus (CBT) through a linker and optionally, a connector molecule. | 2011-08-18 |
20110201564 | SUBSTITUTED 7-SULFANYLMETHYL, 7-SULFINYLMETHYL AND 7-SULFONYLMETHYL INDOLES AND USE THEREOF - The present application relates to novel 7-sulfanylmethyl-, 7-sulfinylmethyl- and 7-sulfonylmethylindole derivatives, processes for the preparation thereof, the use thereof alone or in combinations for the treatment and/or prevention of diseases, and the use thereof for the manufacture of medicaments for the treatment and/or prevention of diseases, especially for the treatment and/or prevention of cardiovascular disorders. | 2011-08-18 |
20110201565 | LUTEOLIN AND DIOSMIN/DIOSMETIN AS NOVEL STAT3 INHIBITORS FOR TREATING AUTISM - The present invention includes methods for the treatment of autoimmune disorders such as autism, schizophrenia, and type 1 diabetes. Flavonoids, luteolin, diosmin, and diosmin's aglycone form, diosmetin, were found to inhibit activation/phosphorylation of STAT3 induced by IL-6 in cultured neuronal cells. Furthermore, mice treated with diosmin showed a significant reduction of autistic phenotype induced by IL-6 through inhibition of STAT3 activation. | 2011-08-18 |
20110201566 | METHODS FOR TREATING RESISTANT DISEASES USING TRIAZOLE CONTAINING MACROLIDES - Triazole-containing macrolide and ketolide antibiotics, therapeutic compositions containing them and methods of use for treating diseases caused by one or more resistant organisms are described. | 2011-08-18 |
20110201567 | Ivermectin Antagonizes Ethanol Inhibition in P2X4 Receptors - A method for reducing alcohol consumption in a subject includes a step of identifying a subject exhibiting at least one symptom of alcoholism and then administering a therapeutically effective amount of an Ivermectin analogue-containing composition to the subject. A method of screening Ivermectin analogues for reducing alcohol consumption is also provided. | 2011-08-18 |
20110201568 | PHYOTOCHEMICAL COMPOSITION AND A PROCESS THEREOF - The present invention is successful in providing caffeic acid derivatives namely eicosanyl caffeate and docosyl caffeate from | 2011-08-18 |
20110201569 | Methods For Treating Myocardial Disorders - Provided are methods for treating myocardial disorders comprising administering to a subject an effective amount of a compound of formula (I) | 2011-08-18 |
20110201570 | NUCLEUS PULPOSUS FILLER - The present invention provides a nucleus pulposus filler or the like which is to be packed into an area in deformed intervertebral disc wherein normal nucleus should be located and can be stabley maintained for a long time More preferably, the present invention provides a nucleus pulposus filler comprising a crosslinked chondroitin sulfate as an active ingredient. The photocrosslinked chondroitin sulfate is preferably the following one: a photocrosslinked chondroitin sulfate obtainable by freezing a photoreactive chondroitin sulfate-containing solution comprising: a photoreactive chondroitin sulfate to which a photoreactive group is bound; an aqueous solvent capable of dissolving the photoreactive chondroitin sulfate; and any one substance selected from the group consisting of an alcohol having aqueous solvent miscibility, a surfactant, and a cheleting agent; irradiating the resulting frozen product with light; and then melting the frozen product. The filler can be provided as a kit by packing it into a container from which the filler can be pushed out. | 2011-08-18 |
20110201571 | HEAT STERILISED INJECTABLE COMPOSITION OF HYALURONIC ACID OR ONE OF THE SALTS THEREOF, POLYOLS AND LIDOCAINE - An injectable aqueous composition of hyaluronic acid or one of the salts thereof, one or more polyol(s) and lidocaine is used for cosmetic purposes or for therapeutic purposes. It has improved viscoelastic rheological properties and long in vivo persistence. The polyol is chosen, for example, from glycerol, sorbitol, propylene glycol, mannitol, erythritol, xylitol, maltitol and lactitol. The particular properties are obtained by heat sterilising the mixture. | 2011-08-18 |
20110201572 | PHARMACEUTICAL COMPOSITION WITH GLYCOSAMINOGLYCANS AND USE THEREOF IN THE TREATMENT OF CHRONIC ULCERS - The invention relates to a composition of glycosaminoglycans for the treatment of diabetic foot ulcer, it specifically relates to low molecular weight heparins (LMWHs) and very low molecular weight heparins (VLMWHs) in the treatment of chronic ulcers, particularly of diabetic foot ulcers, and more specifically in the manufacture of a medicinal product for the treatment of chronic ulcers, and particularly diabetic foot ulcers and pressure ulcers. | 2011-08-18 |
20110201573 | MIXTURES OF POLYSACCHARIDES DERIVED FROM HEPARIN, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - The present invention relates to mixtures of polysaccharides derived from heparin having a mean molecular weight of 1500 to 3000 Daltons and an anti-Xa/anti-IIa ratio greater than 30, their method of preparation and pharmaceutical compositions containing them. | 2011-08-18 |
20110201574 | FATTY ACID AMIDE HYDROLASE INHIBITORS - The present invention provides fatty acid amide hydrolase inhibitors, solid forms thereof, compositions thereof, and methods of making and using the same. | 2011-08-18 |
20110201575 | STABILIZED SOLID DISPERSION OF ADEFOVIR DIPIVOXIL AND PREPARATION METHOD THEREOF - The present invention relates to an amorphous solid dispersion with improved stability comprising 9-[2-[[bis[(pivaloyloxy)methyl]phosphono]methoxy]ethyl]adenine as a nucleotide analogue, a pharmaceutical composition comprising the same, and a method for preparing the same. | 2011-08-18 |
20110201576 | Small molecule inhibitors of stat3 with anti-tumor activity - The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of Stat3 signaling, Stat3 dimerization, Stat3-DNA binding, Stat5-DNA binding, and/or aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but are not limited to, NSC 74859 (S3I-201), NSC 42067, NSC 59263, NSC 75912, NSC 11421, NSC 91529, NSC 263435, and pharmaceutically acceptable salts and analogs of the foregoing. Other non-malignant diseases characterized by proliferation of cells that may be treated using the compounds of the invention, but are not limited to, cirrhosis of the liver; graft rejection; restenosis; and disorders characterized by a proliferation of T cells such as autoimmune diseases, e.g., type 1 diabetes, lupus and multiple sclerosis. The invention further includes an in-vitro screening test for the presence of malignant cells in a mammalian tissue; a method of identifying inhibitors of constitutive Stat3 activation, Stat3-DNA binding, Stat5-DNA binding, and/or Stat3 dimerization; and a method of identifying anti-cancer agents. | 2011-08-18 |
20110201577 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF OSELTAMIVIR AND ANALOGS THEREOF - The present application relates to processes for the preparation of oseltamivir and the H | 2011-08-18 |
20110201578 | COMPOSITION AND METHODS FOR THE TREATMENT OF PSEUDOFOLLICULITIS BARBAE AND SKIN IRRITATION - The invention comprises a composition for the treatment of pseudofolliculitis barbae and a method of use therefor. Preferred embodiments include compositions containing one or more of active ingredients L-arginine, acetylsalicyclic acid, and salicyclic acid adjusted to a pH in the range of 4.0 to 6.0. Preferred compositions include: a carrier, such as water; a moisturizer, such as propylene glycol, and one or more of the active ingredients. Application of a composition for the treatment of pseudofolliculitis barbae with a pH of about skin does not disrupt normal skin functioning. | 2011-08-18 |
20110201579 | Method of Improving the Overall Health of a Patient by Application of Pregnenolone - A method is described herein for improving the overall health of a patient by providing subcutaneous pellets containing pregnenolone to at least one part of the body of the patient. In another embodiment, pregnenolone is mixed with DHEA into a cream and the resulting pregnenolone/DHEA cream is applied to at least one part of a body. | 2011-08-18 |
20110201580 | PYRROLIDINE DERIVATIVES - The present invention relates to novel anti-inflammatory and antiallergic compounds of the glucocorticosteroid series, methods of preparing such compounds, pharmaceutical compositions comprising them, combinations and therapeutic uses thereof. More particularly, the invention relates to glucocorticosteroids that are derivatives of pyrrolidine. | 2011-08-18 |
20110201581 | Novel Compounds 010 - The present invention provides compounds of formula (I) | 2011-08-18 |
20110201582 | METHOD AND COMPOSITION FOR TREATMENT OF SKIN CONDITIONS - A method for treating dermatological conditions as eczema, seborrheic dermatitis, psoriasis and allergic skin reactions such as hives, skin irritations, poison ivy, poison oak, and the like. The method involves applying to the affected area of the skin a few drops of a combination of pheniramine maleate and either naphazoline HCL or phenylephrine HCL and then applying to the same affected area a topical corticosteroid cream, ointment or lotion. The preferred ratio is approximately one drop of solution for every approximately 0.1 grams of topical corticosteroid cream applied to each patch of skin affected with any of the dermatological conditions. | 2011-08-18 |
20110201583 | GUANIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS - The invention provides compounds of formula I: | 2011-08-18 |
20110201584 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS - Chemical entities that are bufalin derivatives, pharmaceutical compositions and methods of treatment of cancer are described. | 2011-08-18 |
20110201586 | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING HYPOGONADISM - A pharmaceutical composition useful for treating hypogonadism is disclosed. The composition comprises an androgenic or anabolic steroid, a C1-C4 alcohol, a penetration enhancer such as isopropyl myristate, and water. Also disclosed is a method for treating hypogonadism utilizing the composition. | 2011-08-18 |
20110201587 | HSP90 INHIBITORS AND METHODS OF USE - The present invention provides methods for treating various clinical conditions associated with biological activity of HSP90 in a subject. Such methods include administering to the subject in need of such a treatment a therapeutically effective amount of a composition comprising an HSP90 inhibitor. | 2011-08-18 |
20110201588 | Post Foaming Gel Composition Comprising An Anti-Irritation Agent - A personal care composition which is preferably a post-foaming gel, said composition comprising an anti-irritation agent; a water dispersible surface active agent, of a carrier comprising water; and optionally a lubricant. | 2011-08-18 |
20110201589 | NEW BRADYKININ B1 ANTAGONISTS - The invention relates to compounds of formula (I) wherein R | 2011-08-18 |
20110201590 | SUBSTITUTED AMINOINDANES AND ANALOGS THEREOF, AND THE PHARMACEUTICAL USE THEREOF - The invention relates to substituted aminoindanes and analogs thereof of formula (I) and the pharmaceutical use thereof. Medicaments which comprise compounds of this type are suitable for the prevention or treatment of diverse disorders such as, for example, of respiratory disorders, cystic fibrosis disorders, acute or chronic renal disorders or bowel disorders. | 2011-08-18 |
20110201591 | ISONICOTINAMIDE OREXIN RECEPTOR ANTAGONISTS - The present invention is directed to isonicotinamide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved. | 2011-08-18 |
20110201592 | Therapeutic Oxy-Phenyl-Aryl Compounds and Their Use - The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain oxy phenyl aryl compounds (referred to herein as OPA compounds), as described herein, which, inter alia, inhibit Checkpoint Kinase 2 (CHK2) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK2 kinase function, and in the treatment of diseases and conditions that are mediated by CHK2, that are ameliorated by the inhibition of CHK2 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or TS inhibitor; (d) a microtubule targeted agent; and (e) ionising radiation. | 2011-08-18 |
20110201593 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF - The invention provides novel compounds of formula I having the general formula: | 2011-08-18 |
20110201594 | PYRIDO [2,3-D] PYRIMIDINES AND THEIR USE AS KINASE INHIBITORS - The present invention provides derivatives of pyrido[2,3-d]pyrimidin-7-one. These compounds are kinase inhibitors, including compounds that show anti-proliferative activity, including against tumor cells, and are useful in the treatment of diseases including cancer. | 2011-08-18 |
20110201595 | OXAZOLIDINYL ANTIBIOTICS - The invention relates to antibacterial compounds of formula I | 2011-08-18 |
20110201596 | Methods for Providing Oxidatively Stable Ophthalmic Compositions - This invention relates to a process for improving the stability of an ophthalmically compatible solution comprising at least one oxidatively unstable ophthalmic compound. | 2011-08-18 |
20110201597 | METHOD AND COMPOSITION FOR TREATING ALZHEIMER-TYPE DEMENTIA - There is described a method for increasing the maximal tolerated dose and thus the efficacy of an acetylcholinesterase inhibitor (AChEI) in a patient suffering from an Alzheimer type dementia by decreasing concomitant adverse effects by administration of said AChEI in combination with a non-anticholinergic antiemetic agent, whereby an enhanced acetylcholinesterase inhibition in the CNS of said patient is achieved and alleviation of the symptoms of Alzheimer type dementia in said patient is thereby improved to a greater extent. The use of a non-anticholinergic antiemetic agent for the preparation of a pharmaceutical composition for the treatment of Alzheimer type dementia in combination with an acetylcholinesterase inhibitor (AChEI) and pharmaceutical compositions comprising (a) a 5HT | 2011-08-18 |
20110201598 | Pharmaceutical Compositions Comprising RET Inhibitors and Methods for the Treatment of Cancer - A class of compounds useful in pharmaceutical compositions and methods for treating or preventing cancer is described. The compounds' ability to inhibit RET kinase is quantified, i.e., their respective RET IC50 and EC50 values are described. One such compound, known as cyclobenzaprine and herein as SW-01, has been identified as RET-specific with an IC50 of 300 nM. SW-01 inhibits RET autophosphorylation and blocks the growth and transformation of thyroid cancer cell lines. It has been further tested in pancreatic cancer, breast cancer, and SCLC cell lines. The compounds show utility for inhibition of survival and proliferation of tumour cells. | 2011-08-18 |
20110201599 | CDK Modulators - A compound according to Formula I: or a pharmaceutically-acceptable salt thereof, wherein R1, R3, A, B and D are as defined in the specification; pharmaceutical compositions thereof, and methods of use thereof. | 2011-08-18 |
20110201600 | CHALCONE LINKED PYRROLO[2,1-C][1, 4]BENZODIAZEPINE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF - The present invention relates to chalcone linked pyrrolo[2,1-c][1,4]benzodiazepine hybrids and a process for the preparation there of. More particularly it relates to 7-Methoxy-8-{n[4-1-(2 or 4-substituted phenyl)-3-(4-hydroxy-3-methoxyphenyl)-2-propen-1-one]alkyl}-oxy}-(11aS)-1,2,3,11a-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one and 7-Methoxy-8-{n[-3-(4-hydroxy-3-methoxyphenyl)-1-(2,4-alkyl-3-quinolyl)-2-propen-1-one]alkyl}-oxy-(11aS)-1,2,3,11a-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one with aliphatic chain length variations useful as anticancer (antitumour) agent. The general structural formula of these chalcone linked pyrrolo[2,1-c][1,4]benzodiazepines hybrids is given below. wherein R | 2011-08-18 |
20110201601 | INHIBITORS OF THE SHIGA TOXINS TRAFFICKING THROUGH THE RETROGRADE PATHWAY - The present invention relates to the use of compounds of general formula (I) and (II) for the preparation of a drug for preventing and/or treating disorders caused by Shiga toxins and related toxins. | 2011-08-18 |
20110201602 | PROTEIN KINASE MODULATORS AND METHOD OF USE - The present invention relates to chemical compounds having a general formula I | 2011-08-18 |
20110201603 | Novel Acylaminobenzamide Derivatives - The present invention relates to novel Acylaminobenzamide derivatives represented by the following formula (I) and use thereof as pesticides: wherein V represents an aromatic ring group of V1 to V5 described in the detailed description, Q represents an aromatic ring group of Q1 to Q7 described in the detailed description, G | 2011-08-18 |
20110201604 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof - Substituted fused imidazole derivatives, methods of their preparation, pharmaceutical compositions comprising a substituted fused imidazole derivative, and methods of use in treating inflammation are provided. The substituted fused imidazole derivatives may control the activity or the amount or both the activity and the amount of heme-oxygenase. | 2011-08-18 |
20110201605 | HETEROARYL SUBSTITUTED PIPERIDINES - The invention relates to compounds of formula | 2011-08-18 |
20110201606 | PYRIMIDINE DERIVATIVES - Novel pyrimidine derivatives of formula I | 2011-08-18 |
20110201607 | FUSED HETEROCYCLIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS - The present invention is directed to fused heterocyclic compounds of formula (I): which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor. | 2011-08-18 |
20110201608 | SUBSTITUTED NAPHTHYRIDINES AND USE THEREOF AS MEDICINES - The invention relates to new substituted naphthyridines of formula 1, as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, | 2011-08-18 |
20110201609 | PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS - The subject invention concerns compounds having activity as inhibitors of proteasomes and methods of using the subject compounds. In one embodiment, a compound of the invention has the chemical structure shown in formula I: | 2011-08-18 |
20110201610 | ARYL SULFONAMIDES - The present invention relates to compounds that modulate various chemokine receptors. These compounds are useful for treating inflammatory and immune diseases. | 2011-08-18 |
20110201611 | Process for the Preparation of Compositions for Modulating a Kinase Cascade and Methods of Use Thereof - The invention relates to compositions comprising 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide and its mesylate and dihydrochloride salts. More specifically, the invention provides an efficient process for the synthesis of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide and its mesylate and dihydrochloride salts and methods for modulating one or more components of a kinase cascade using the compositions of the invention. | 2011-08-18 |
20110201612 | Compositions for Modulating a Kinase Cascade and Methods of Use Thereof - The invention relates to compositions comprising 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide and its mesylate and dihydrochloride salts. The invention provides an efficient process for the synthesis of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide and its mesylate and dihydrochloride salts and methods for modulating one or more components of a kinase cascade using the compositions of the invention. The present invention also provides a novel polymorph of the mesylate salt of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide (Form A), characterized by a unique X-ray diffraction pattern and Differential Scanning Calorimetry profile, as well as a unique crystalline structure. | 2011-08-18 |
20110201613 | FUNGICIDE HYDROXIMOYL-TETRAZOLE DERIVATIVES - The present invention relates to hydroximoyl-tetrazole derivatives of formula (I), their process of preparation, their use as fungicide active agents, particularly in the form of fungicide compositions and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions. | 2011-08-18 |
20110201614 | CYCLIC GLYCYL-2-ALLYL PROLINE IMPROVES COGNITIVE PERFORMANCE IN IMPAIRED ANIMALS - Embodiments of this invention provide methods for therapeutic use of cyclic G-2-Allyl Proline to treat cognitive disorders as well as manufacture of medicaments including tablets, capsules, injectable solutions that are useful for treatment of such conditions. | 2011-08-18 |
20110201615 | TRIAZOLE BETA CARBOLINE DERIVATIVES AS ANTI-DIABETIC AGENTS - Beta-carboline derivatives of structural formula (I) are selective antagonists of the somatostatin subtype receptor 3 (SSTR3) and are useful for the treatment of Type 2 diabetes mellitus and of conditions that are often associated with this disease, including hyperglycemia, insulin resistance, obesity, lipid disorders, and hypertension. The compounds are also useful for the treatment of depression and anxiety. | 2011-08-18 |
20110201616 | SULFONAMIDE COMPOUNDS OR SALTS THEREOF - [Object] A compound which is useful as an EP1 receptor antagonist is provided. | 2011-08-18 |
20110201617 | Therapeutic Uses Of Compounds Having Combined SERT, 5-HT3 And 5-HT1A Activity - New pharmaceutical uses of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof are provided. | 2011-08-18 |
20110201618 | KMUPS INHIBITING PROLIFERATION AND OBLITERATION OF PULMONARY ARTERY - An obstructive pulmonary disease inhibiting pharmaceutical composition is provided. The obstructive pulmonary disease inhibiting pharmaceutical composition includes: | 2011-08-18 |
20110201619 | Use of N-Phenyl-2-pyrimidineamine Derivatives Against Mast Cell-based Diseases Like Allergic Disorders - Use of the N-phenyl-2-pyrimidine-amine derivatives of formula I, | 2011-08-18 |
20110201620 | 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS - The present invention relates to the use of masitinib or a pharmaceutically acceptable salt thereof, and in particular of masitinib mesylate, for the preparation of a medicament for the treatment of GIST, to the use of this therapy for the treatment of GIST, and a method of treating mammals, including humans, suffering from GIST by administering to said mammal in need of such treatment an effective dose of masitinib, and in particular masitinib mesylate. | 2011-08-18 |
20110201621 | ANGIOTENSIN II RECEPTOR ANTAGONISTS - A compound having the structure | 2011-08-18 |
20110201622 | Solid Forms Comprising A Cyclopropyl Amide Derivative - This disclosure relates to at least one solid form of 4-{(1S, 2S)-2-[((R)-4-cyclobutyl-2-methylpiperazin-1-yl)carbonyl]-cyclopropyl}-benzamide. This disclosure also relates to at least one pharmaceutical composition comprising at least one solid form described herein, methods of using the solid forms and pharmaceutical compositions comprised thereof, and processes of manufacturing the solid forms. | 2011-08-18 |
20110201623 | Crystalline Form Of A Cyclopropyl Benzamide Derivative - The present invention relates to a crystalline form of compound (I), 4-{(1S,2S)-2-[(4-cyclobutylpiperazin- | 2011-08-18 |
20110201624 | Pharmaceutical Composition for Prevention and Treatment of Diabetes or Obesity Comprising a Compound that Inhibits Activity of Dipeptidyl Peptidase-IV, and other Antidiabetic or Antiobesity Agents as Active Ingredients - The present invention relates to a pharmaceutical composition for the prevention and treatment of diabetes or obesity comprising as active ingredients a compound which inhibits the activity of dipeptidyl peptidase-IV (DPP-IV), a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof, and one or more other antidiabetic or antiobesity agents. The pharmaceutical composition exhibits excellent glucose tolerance and may be useful in the prevention and treatment of diabetes, obesity, and the like by effectively inhibiting blood glucose levels and reducing fat mass. | 2011-08-18 |
20110201625 | Organic Comopunds - A compound of Formula I | 2011-08-18 |
20110201626 | 4,6-DIAMINOPYRIMIDINE STIMULATORS OF SOLUBLE GUANYLATE CYCLASE - The present invention relates to new 4,6-diaminopyrimidine stimulators of soluble guanylate cyclase, pharmaceutical compositions thereof, and methods of use thereof. | 2011-08-18 |
20110201627 | FREEZE-DRIED REPARATION OF TETRODOTOXIN AND THE PRODUCING METHOD THEREOF - A stable freeze-dried powder preparation of tetrodotoxin and the producing method thereof. The freeze-dried powder preparation has tetrodotoxin as the main active ingredient, and comprises solubilizer, excipient and stabilizer. The said solubilizer is citric acid. The excipient is sodium chloride, mannitol or their composite. The stabilizer is dextran, trehalose or their composite. The ratio of tetrodotoxin, excipient and stabilizer is 1:150-3000:50-500 or 50-6000. Preferably, the preparation comprises lidocaine hydrochloride as function modulator. The preparation of the present invention can be used for avoiding the dependent abstinence syndrome of drugs such as opiates and cannabis. | 2011-08-18 |
20110201628 | HETEROCYCLIC JAK KINASE INHIBITORS - The present invention relates to compounds of Formula (I) and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds provide a treatment for myeloproliferative disorders and cancer. | 2011-08-18 |
20110201629 | CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS - There are described cyclohexyl amide derivatives of Formula I, | 2011-08-18 |
20110201630 | Fused Pyridine Derivatives as Kinase Inhibitors - A series of heteroaryl-substituted fused pyridine derivatives, in particular heteroaryl-substituted thieno[3,2-6]pyridine derivatives, being selective inhibitors of PO kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions. | 2011-08-18 |
20110201631 | PHARMACEUTICAL FORMULATIONS COMPRISING PEMETREXED - Pharmaceutical formulations comprising amorphous pemetrexed or its salts, and processes to prepare the formulations. | 2011-08-18 |
20110201632 | 2,5-Disubstituted Piperidine Orexin Rceptor Antagonists - The present invention is directed to 2,5-disubstituted piperidine amide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved. | 2011-08-18 |
20110201633 | ALFUZOSIN TABLETS AND SYNTHESIS - A monolithic composition includes alfuzosin in a polymeric matrix adapted to release 13-33% of the alfuzosin within 2 hours, 40-60% of the alfuzosin within 7 hours, and greater than 80% of the alfuzosin within 20 hours of administration. A unit dosage form includes: a heterogeneous mixture of alfuzosin hydrochloride, lactose monohydrate, hydroxypropylmethylcellulose, polyvinylpyrrolidone and magnesium stearate, wherein the heterogeneous mixture is heterogeneously distributed throughout the unit dosage form. A manufacturing process includes: mixing a hydrophilic polymer and alfuzosin to provide a blend; granulating the blend to provide granules; drying the granules on a dryer to provide dried granules; sizing the dried granules to provide sized granules; mixing the sized granules with a lubricant to obtain a mixture; and compressing the mixture to obtain a tablet. A method of treating benign prostatic hyperplasia, includes administering to a patient the composition or unit dosage form once a day. | 2011-08-18 |
20110201634 | DIHYDROPYRIDIMIDINONE COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES AND PROCESS FOR PREPARING THE SAME - The present invention relates to a dihydropyrimidinone compound of formula (I) wherein X represents O, S, etc. and R′ represents alkyl, alkoxy, thioalkyl, thioalkyloxy, phenyl, substituted phenyl, phenyloxy, substituted phenyloxy, amino, monosubstitutedamino, disubstitutedamino, aryl, heteroaryl, aryloxy, heteroaryloxy, halo; R″ represents alkoxy, phenyloxy, substituted phenyloxy, aryloxy, heteroaryloxy, halo, NR | 2011-08-18 |